
FDA Grants Priority Review for ENHERTU Combo in Advanced Breast Cancer
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for …
FDA Grants Priority Review for ENHERTU Combo in Advanced Breast Cancer Read More